[go: up one dir, main page]

WO2014037726A1 - Compositions pharmaceutiques liquides - Google Patents

Compositions pharmaceutiques liquides Download PDF

Info

Publication number
WO2014037726A1
WO2014037726A1 PCT/GB2013/052325 GB2013052325W WO2014037726A1 WO 2014037726 A1 WO2014037726 A1 WO 2014037726A1 GB 2013052325 W GB2013052325 W GB 2013052325W WO 2014037726 A1 WO2014037726 A1 WO 2014037726A1
Authority
WO
WIPO (PCT)
Prior art keywords
carcainium
salt
pharmaceutical composition
tussive
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2013/052325
Other languages
English (en)
Inventor
Peter Lionel Spargo
Lewis Siu Leung Choi
Bertrand Michel Claude PLOUVIER
Edward James FRENCH
Julian Scott Northen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verona Pharma Ltd
Original Assignee
Verona Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2012/052191 external-priority patent/WO2013034910A1/fr
Application filed by Verona Pharma Ltd filed Critical Verona Pharma Ltd
Publication of WO2014037726A1 publication Critical patent/WO2014037726A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Definitions

  • Cough is the most common respiratory ailment for which patients seek medical help. It is a very common problem in medical practice as it accompanies a great variety of viral or bacterial infections including pneumonia, cold, flu and some underlying diseases, such as asthma, emphysema, lung cancer, etc.
  • Cough is a natural response to mechanical and chemical irritation of trachea and bronchi.
  • the physiological role of cough is to prevent aspiration of foreign objects or excess secretion within the respiratory tract and to remove such objects or secretion or exudates from the trachea and bronchi.
  • carcainium salts can in fact provide an effective therapy for cough in humans. That conclusion is based on a new clinical trial in which carcainium chloride is seen to have a statistically significant therapeutic effect in treatment and/or suppression of cough in patients suffering from interstitial lung disease.
  • Pressurized metered dose inhalers are convenient devices for administering drugs to patients by inhalation, and rely on a propellant compound to generate an aerosol for inhalation.
  • the propellant is commonly a hydro fluoroalkane.
  • a pressurized metered dose inhaler can only be used to deliver a drug if that drug can formulated as a suspension or solution in the propellant. This can cause difficulties, since many drugs cannot be formulated as a suspension or solutions in propellants such as a hydrofluoroalkanes.
  • certain specific salts of carcainium can be formulated as suspensions or solutions in propellants such as hydrofluoroalkanes. Such solutions or suspensions are suitable for delivery from pressurized metered dose inhalers.
  • the present invention provides a liquid pharmaceutical composition for use in a pressurized metered dose inhaler (pMDI), which composition comprises a pharmaceutically acceptable addition salt of (i) carcainium, and (ii) sulfuric acid, hydrochloric acid, hydrobromic acid, maleic acid or 1 -hydroxy -2 -naphthoic acid (xinafoic acid).
  • pMDI pressurized metered dose inhaler
  • the invention further provides a pressurized metered dose inhaler comprising a pharmaceutical composition of the invention.
  • the invention further provides a pharmaceutically acceptable addition salt of (i) carcainium, and (ii) sulfuric acid, hydrobromic acid, maleic acid or l-hydroxy-2-naphthoic acid (xinafoic acid).
  • the invention further provides a pharmaceutical composition or carcainium salt of the invention, for use in the treatment of the human or animal body.
  • the invention further provides a pharmaceutical composition or carcainium salt of the invention, for use in the treatment and/or suppression of cough, tussive attacks or tussive episodes.
  • the invention further provides use of pharmaceutical composition or carcainium salt of the invention in the manufacture of a medicament for the treatment and/or suppression of cough, tussive attacks or tussive episodes.
  • the invention further provides a method of treatment and/or suppression of cough, tussive attacks or tussive episodes in a patient, which method comprises administering to said patient a therapeutically effective amount of pharmaceutical composition or carcainium salt of the invention.
  • Figures 1 to 3 show the X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) patterns for carcainium maleate prepared in Example 1.
  • XRPD X-ray powder diffraction
  • DSC differential scanning calorimetry
  • TGA thermogravimetric analysis
  • Figures 4 to 6 show the X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) patterns for carcainium oxalate prepared in Example 1.
  • XRPD X-ray powder diffraction
  • DSC differential scanning calorimetry
  • TGA thermogravimetric analysis
  • Figures 7 to 9 show the X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) patterns for carcainium fumarate prepared in Example 1.
  • Figures 10 to 12 show the X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) patterns for carcainium sulfate prepared in Example 1.
  • Figures 13 to 15 show the X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) patterns for carcainium bromide prepared in Example 1.
  • XRPD X-ray powder diffraction
  • DSC differential scanning calorimetry
  • TGA thermogravimetric analysis
  • Figure 16 shows the inhibition cough by carcainium salts in guinea pigs, as described in Example 5. Each bar represents the mean and the vertical lines represent standard error (SEM) for the guinea pigs tested.
  • Carcainium is the compound N,N-Bis-(phenylcarbamoylmethyl) dimethylammonium and has the following structure.
  • the liquid pharmaceutical compositions of the invention comprise a pharmaceutically acceptable addition salt of (i) carcainium, and (ii) sulfuric acid, hydrochloric acid, hydrobromic acid or 1 -hydroxy-2-naphthoic acid (xinafoic acid).
  • the salt present in the composition is thus carcainium sulfate, carcainium chloride, carcainium bromide or carcainium 1 -hydroxy-2- naphthoate (ie. carcainium xinafoate).
  • the carcainium sulfate salt typically has a stoichiometry of 2:1 carcainium:sulfate.
  • the carcainium chloride salt typically has a stoichiometry of 1 :1 carcainium:chloride.
  • the carcainium bromide salt typically has a stoichiometry of 1 :1 carcainium:bromide.
  • the carcainium xinafoate salt typically has a stoichiometry of 1 :1 carcainium:xinafoate.
  • the stoichiometry of the salts can be determined by techniques known to those skilled in the art, such as 1H NMR.
  • the liquid pharmaceutical compositions of the invention are for use in pressurized metered dose inhalers (pMDIs).
  • the liquid pharmaceutical compositions therefore comprise a propellant.
  • the propellant provides the force to generate the aerosol cloud when the pMDI is actuated.
  • Suitable propellants can be selected by those skilled in the art.
  • the propellant is a hydrofluoroalkane.
  • Preferred propellants are 1,1,1,2,-tetrafluoroethane (HFA 134a) and 1,1,1,2,3,3,3-heptafluoropropane (HFA 227) or mixtures thereof.
  • HFA 134a 1,1,1,2,-tetrafluoroethane
  • HFA 227 1,1,1,2,3,3,3-heptafluoropropane
  • compositions of the invention typically comprises 1,1,1,2,-tetrafluoroethane and/or 1 ,1 ,1 ,2,3,3,3-heptafluoropropane.
  • the liquid pharmaceutical composition contains 1 ,1 ,1 ,2,-tetrafluoroethane as the sole propellant, or 1,1,1,2,3,3,3-heptafluoropropane as the sole propellant, or a 1 :1 mixture of 1 ,1 ,1,2,-tetrafluoroethane and 1,1,1,2,3,3,3- heptafluoropropane as the sole propellant.
  • the carcainium salt is typically suspended or dissolved in the propellant.
  • the liquid composition is thus typically a suspension of the carcainium salt or a solution of the carcainium salt.
  • the carcainium salt is typically carcainium sulfate, carcainium chloride or carcainium bromide, preferably carcainium sulfate or carcainium chloride, most preferably carcainium sulfate.
  • the fine particle fraction of the particles in the suspension of carcainium salt is preferably greater than 10%, more preferably greater than 15%.
  • the FPF is the proportion of particles which are less than 5 ⁇ in size.
  • the FPF can readily be determined by techniques known to those skilled in the art, for example using an impactor.
  • the carcainium salt is typically carcainium xinafoate, carcainium maleate, carcainium chloride or carcainium bromide, preferably carcainium xinafoate, carcainium maleate, or carcainium chloride, more preferably carcainium xinafoate or carcainium maleate, most preferably carcainium xinafoate.
  • the liquid pharmaceutical composition of the invention optionally comprises additional components.
  • the liquid pharmaceutical composition may optionally comprise a surfactant (such as TWEEN) or an organic solvent (such as ethanol).
  • the liquid pharmaceutical composition of the invention is preferably delivered to a patient using a pressurized metered dose inhaler.
  • the invention thus also relates to a pressurized metered dose inhaler comprising the liquid pharmaceutical composition of the invention.
  • the aerosol delivered from the pressurized metered dose inhaler typically has droplets which have a mass median aerodynamic diameter (MMAD) of from about 1 ⁇ to about 10 ⁇ , preferably from about 3 ⁇ to about 10 ⁇ , more preferably from about 4 ⁇ to about 5.5 ⁇ , or from about 5 ⁇ to about 10 ⁇ , or from about 5.5 ⁇ to about 10 ⁇ or from about 6 ⁇ to about 10 ⁇ .
  • the mass median aerodynamic diameter (MMAD) can be measured by any suitable technique known to those skilled in the art, such as laser diffraction. Such particle sizes are preferred for effective delivery of the drug into the conducting and central airways.
  • compositions and carcainium salts of the invention are useful for the treatment and/or suppression of cough, tussive attacks or tussive episodes, preferably in a human patient.
  • Carcainium salts have efficacy as anti-tussives in human patients at dosages at which the salts have no local anaesthetic activity. Accordingly, the present invention also provides a said pharmaceutical composition or carcainium salt for use in the treatment and/or suppression of cough, tussive attacks or tussive episodes in a patient, wherein said carcainium salt acts by a mechanism independent of local anaesthesia.
  • the invention also provides a pharmaceutical composition or carcainium salt of the invention for use in the treatment and/or suppression of cough, tussive attacks or tussive episodes in a patient, without causing any substantial local anaesthetic effect.
  • Local anaesthetic activity in inhaled medicaments causes side effects such as oropharyngeal numbing, impairment or loss of gag reflex and/or impairment or loss of the tracheal aspiration reflex.
  • said carcainium salt is for use in the treatment and/or suppression of cough, tussive attacks or tussive episodes in a patient, without causing any substantial oropharyngeal numbing, impairment or loss of gag reflex and/or impairment or loss of the tracheal aspiration reflex.
  • said pharmaceutical composition or carcainium salt is for use in the treatment and/or suppression of cough, tussive attacks or tussive episodes in a patient suffering from or susceptible to bronchospasm, oropharyngeal numbing, impairment or loss of gag reflex and/or impairment or loss of the tracheal aspiration reflex, and more typically in a patient suffering from or susceptible to oropharyngeal numbing, impairment or loss of gag reflex and/or impairment or loss of the tracheal aspiration reflex.
  • the pharmaceutical composition or carcainium salt is particularly effective in such patients, and also due to the low systemic side effects associated with the invention.
  • said pharmaceutical composition or carcainium salt is for use in the treatment and/or suppression of cough, tussive attacks or tussive episodes in a patient, wherein said salt is (a) for use during a surgical or invasive procedure, or (b) for chronic use.
  • a preferred surgical or invasive procedure where said carcainium salt can be used is bronchoscopy.
  • Chronic use typically means administration of said carcainium salt twice a day or more, for example up to five times per day, or administration of said carcainium salt once a day or more over a period of one week or more, for example over a period of two weeks or more.
  • the pharmaceutical composition or carcainium salt is administered such that systemic exposure of carcainium salt following delivery to the patient as measured by peak plasma concentration is less than 800 ng/ml, more preferably less than 500 ng/ml, more preferably less than 100 ng/ml, and most preferably less than 70 ng/ml.
  • peak plasma concentration is less than 800 ng/ml, more preferably less than 500 ng/ml, more preferably less than 100 ng/ml, and most preferably less than 70 ng/ml.
  • concentration of carcainium salt can be measured by any suitable technique known to those skilled in the art, such as a liquid chromatography/tandem mass spectrometry (LC/MS/MS) assay method.
  • LC/MS/MS liquid chromatography/tandem mass spectrometry
  • the origin of the cough to be treated by the present invention is not particularly limited, and can include virtually any respiratory disorder, such as chronic obstructive pulmonary disease, asthma, tuberculosis, bronchitis, bronchiectasis, suppurative pulmonary disease, respiratory malignancies, allergy, cystic fibrosis, pulmonary fibrosis, respiratory tract inflammation, emphysema, pneumonia, lung cancer, lung neoplasia, sore throat, common cold, influenza, respiratory tract infection, bronchoconstriction, sarcoidosis, smoker's cough, chronic non-productive cough, neoplastic cough; cough due to gastroesophageal reflux, inhalation of irritants, smoke, smog, dust, presence of foreign bodies, air pollution or angiotension converting enzyme (ACE) inhibitor therapy, or acute or chronic cough resulting from or connected with a viral or bacterial infection of the upper airways; or intractable cough resulting from or connected with another underlying disease.
  • the underlying disease may be chronic obstructive pulmonary disease, asthma, tuberculosis, bronchitis, bronchiectasis, suppurative pulmonary disease, respiratory
  • malignancies allergy, cystic fibrosis, pulmonary fibrosis, respiratory tract inflammation, emphysema, pneumonia, lung cancer, lung neoplasia, soar throat, common cold, influenza, respiratory tract infection, bronchoconstriction, sarcoidosis, gastroesophageal reflux, smoker's cough, chronic non-productive cough, neoplastic cough, or acute or chronic cough resulting from or connected with a viral or bacterial infection of the upper airways.
  • the origin of the cough to be treated by the present invention may be interstitial lung disease.
  • the cough, tussive attacks or tussive episodes result from interstitial lung disease.
  • Interstitial lung diseases affect the interstitium, which is the tissue and space around the air sacs of the lungs, and in particular the alveolar epithelium, pulmonary capillary endothelium, basement membrane, perivascular and perilymphatic tissues.
  • Interstitial lung disease may be irritant-induced (for example by silica dust or asbestos) or drug induced (for example by antibiotics, chemotherapeutic drugs, antiarrhythmic agents, or statins).
  • Interstitial lung disease may also arise from connective tissue diseases (such as systemic sclerosis, polymyositis, dermatomyositis, systemic lupus erythematosus or rheumatoid arthritis), from infection (such as atypical pneumonia, Pneumocystis pneumonia (PCP), tuberculosis, chlamydia trachomatis or respiratory syncytial virus) or from malignancy ( such a lymphangitic carcinomatosis).
  • Interstitial lung disease may also be idiopathic, arising from for example sarcoidosis, idiopathic pulmonary fibrosis, Hamman-Rich syndrome or Antisynthetase
  • the pharmaceutical composition or carcainium salt is administered such that substantially whole dose of the drug is delivered to specific target areas, namely the trachea, carina and bronchi, while minimizing the deposition of the drug in other areas where it could cause undesirable local side effects or more easily enter the systemic circulation and cause undesirable side effects.
  • An aerosol preferably delivered by pressurized metered dose inhaler, which has particles having a mass median aerodynamic diameter (MMAD) of from about 1 ⁇ to about ⁇ , typically from about 3 ⁇ to about 10 ⁇ , is preferred.
  • MMAD mass median aerodynamic diameter
  • the carcainium salt is thus typically targeted to the conducting and central airways of the patient.
  • the central airways are the region of the respiratory tract defined by trachea, carina and bronchi.
  • the carina means the ridge separating the opening the right and left main bronchi at their junction with the trachea.
  • the carcainium salt is typically delivered to the patient such that it does not cause bronchospasm, oropharyngeal numbing, impairment or loss of gag reflex, impairment or loss of the tracheal aspiration reflex or systemic exposure that leads to adverse side effects.
  • Efficacy of administration of carcainium salt is measured by the amount of the drug needed for cough abatement, by the frequency of administration needed to suppress tussive attacks or episodes, by the time necessary for delivery of the drug amount and by the percentage of the drug deposited in the specific target areas, namely in trachea, carina and bronchi as well as a lack of deposition in the other areas.
  • the magnitude of the therapeutic or prophylactic dose of carcainium salt required for the treatment and/or suppression of cough, tussive attacks or tussive episodes in a patient will depend upon the severity and nature of the condition being treated and the route of
  • the daily dose and the frequency of the dosing will also vary according to age, body weight and response of the individual patient.
  • the daily dose is determined based on the weight of the patient.
  • the daily dose is 0.5 to 5 mg/kg, for example about 1.0 mg/kg, based on the weight of the patient.
  • the total daily dose of carcainium salt is from about 5 mg to about 300 mg. This may be delivered in a single dose or in repeated doses, for example up to five times a day, but is preferably delivered as a single dose.
  • daily dose it is meant the total quantity of compound of the invention administered to the patient in a day.
  • the daily dose is a single metered nominal dose of from about 5 mg to about 300 mg.
  • a metered nominal dose refers to the quantity of drug substance contained in the metering chamber of the delivery device and is normally expressed as quantity per actuation.
  • the drug substance Upon actuation, the drug substance leaves the device and becomes available to the patient as a "delivered dose".
  • the delivered dose is normally smaller than the metered nominal dose, due to the mechanics of the device.
  • the delivered dose is the amount of the drug which is available at the mouth for inhalation.
  • the delivered dose can be measured using standard techniques known to those skilled in the art. Typically, the delivered dose is from about 4.5 mg to about 275 mg.
  • the invention also provides a pressurised metered dose inhaler comprising pharmaceutical composition of the invention, which inhaler delivers an aerosol of carcainium salt and wherein the particles present in said aerosol have a mass median aerodynamic diameter (MMAD) of from about 1 ⁇ to about ⁇ and which inhaler is configured to deliver (a) a etered nominal dose of about 5 mg to about 300 mg carcainium salt, and/or (b) a delivered dose of about 4.5 mg to about 275 mg carcainium salt.
  • MMAD is from about 3 ⁇ to about 10 ⁇ , more preferably from about 5 ⁇ to about 10 ⁇ , or from about 5.5 ⁇ to about 10 ⁇ or from about 6 ⁇ to about 10 ⁇
  • a maintenance dose of carcainium salt may be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained. When the symptoms have been alleviated to the desired level, treatment should cease. The patient may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.
  • the total daily usage of the carcainium salt will be decided by the attending physician within the scope of sound medical judgment.
  • the specific dose for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts.
  • any suitable route of administration may be employed to provide an effective dosage of the compounds of the present invention, although administration by inhalation is preferred, most preferably in aerosol form.
  • Suitable forms of administration include, but are not limited to, inhalation (delivered by, e.g., metered dose inhaler, jet nebulizer, ultrasonic nebulizer, dry powder inhaler, etc.), nasal sprays, nebulization, oral administration such as via tablets, capsules, lozenges, syrups, sprays, suspensions, elixirs, gargles, and other liquid preparations, aerosol foams, parental administration, and sublingual administration. Administration by inhalation is preferred. Topical administration to the lung via inhalation, typically using a pressurized metered-dose inhaler is particularly preferred.
  • compositions of the present invention can include pharmaceutically acceptable carriers and other conventional additives, including aqueous based carriers, co- solvents such as ethyl alcohol, propylene glycol and glycerin, fillers, lubricants, wetting agents, flavoring agents, coloring agents, emulsifying, suspending or dispersing agents, suspending agents, etc.
  • pharmaceutically acceptable diluents, carriers, and/or propellants may be included in the compositions for use in appropriate devices. These are prepared by procedures well known to those skilled in the art (see e.g., Medication Teaching Manual, 5th Ed., Bethesda, Md., American Society of Hospital Pharmacists, 1991).
  • compositions of the present invention may optionally include other known therapeutic agents, including decongestants such as pseudoephedrine HC1, phenylephrine HC1 and ephedrine HC1, non-steroidal anti-inflammatory drugs such as acetaminophen, aspirin, phenacetin, ibuprofen and ketoprofen, expectorants such as glyceryl guaiacolate, terpin hydrate and ammonium chloride, antihistamines such as chlorpheniramine maleate, doxylamine succinate, brompheniramine maleate and diphenhydramine hydrochloride.
  • decongestants such as pseudoephedrine HC1, phenylephrine HC1 and ephedrine HC1
  • non-steroidal anti-inflammatory drugs such as acetaminophen, aspirin, phenacetin, ibuprofen and ketoprofen
  • expectorants such as glyceryl
  • the pharmaceutical composition or carcainium salt of the invention can be administered in combination with (a) one or more additional anti-tussive agents and/or (b) one or more bronchodilators.
  • Preferred additional anti-tussive agents are menthol or codeine.
  • a preferred bronchodilator is N- ⁇ 2-[(2E)-2-(mesitylimino)-9, 10-dimethoxy-4-oxo-6,7-dihydro-2H- pyrimido[6,l-a]-isoquinolin-3(4H)-yl]ethyl ⁇ urea (which is known by the code RPL-554).
  • the present invention also provides a combination comprising a
  • composition or carcainium salt of the invention and (a) one or more additional anti-tussive agents and/or (b) one or more bronchodilators.
  • the combination is preferably for use in the treatment and/or suppression of cough, tussive attacks or tussive episodes in a patient.
  • the invention further provides a pharmaceutical composition or carcainium salt of the invention for use in the treatment and/or suppression of cough, tussive attacks or tussive episodes in a patient, by co-administration with (a) one or more additional anti-tussive agents, and/or (b) one or more bronchodilators.
  • Co-administration can be simultaneous, concurrent, separate or sequential.
  • the invention further provides (a) one or more additional anti-tussive agents and/or (b) one or more bronchodilators, for use in the treatment and/or suppression of cough, tussive attacks or tussive episodes in a patient, by co-administration with a pharmaceutical composition or carcainium salt of the invention.
  • Co-administration can be simultaneous, concurrent, separate or sequential.
  • the present invention further provides a product comprising a pharmaceutical composition or carcainium salt of the invention and (a) one or more additional anti -tussive agents and/or (b) one or more bronchodilators, as a combined preparation for simultaneous, concurrent, separate or sequential use in the treatment and/or suppression of cough, tussive attacks or tussive episodes in a patient.
  • the salts of the invention can be prepared using the methods and procedures described herein, or using similar methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.
  • carcainium salts such as carcainium chloride can be synthesized as described in the Examples below.
  • techniques such as those described in US
  • the aim of the clinical study was to determine the clinical effectiveness and safety of carcainium chloride by the inhaled route in hospital in-patients with intractable, persistent cough due to interstitial lung disease.
  • VAS visual analogue scale
  • Carcainium chloride is a fine white dry powder and was provided in tightly closed vessels and stored in dark at room temperature upon receipt.
  • the vehicle used for the dilution of carcainium chloride and for the placebo was 0.9 % NaCl injection.
  • Carcainium chloride aerosols corresponding to those used in the above clinical study were generated from the same drug product batch and using the same ultrasonic nebulizer (DeVilbiss Ultraneb).
  • the particle size distributions of these carcainium chloride aerosols were measured and analyzed using a Malvern Spraytec with inhalation cell attachment system. Results from two replicate experiments showed an average value of about 5.38 ⁇ for the Spraytec volume median diameter [Dv(50)].
  • Dv(50) Spraytec volume median diameter
  • MMAD average mass median aero
  • LC/MS/MS liquid chromatography/tandem mass spectrometry
  • carcainium chloride was dissolved in deionized water to provide an initial standard or quality control (QC) stock solution at a concentration of 1000 ⁇ g/mL.
  • QC quality control
  • Serial dilutions were carried out with deionized water to provide secondary stock solutions for subsequent preparation of plasma calibration standards or QC samples according to Table 1 below.
  • the internal standard lidocaine was dissolved in deionized water to provide an initial stock solution at a concentration of 1000 ⁇ g/mL.
  • the initial internal standard stock solution was then serially diluted with deionized water to provide a spiking stock solution concentration of 50
  • K 2 EDTA plasma (100 ⁇ .) was then added to each tube. A 50 ⁇ ⁇ aliquot of of lidocaine internal standard spiking stock solution was transferred to each tube except for blank samples. A 50 ⁇ ⁇ aliquot of deionized water was added to blank samples. Samples were then vortex mixed.
  • the supernatant was dried under a gentle stream of nitrogen to complete dryness using a Turbovap or under a gentle stream of air using an air dryer.
  • Each sample was reconstituted with 100 ⁇ of a 1 : 4 (v/v) mixture of 0.1 % FA in MeOH: 0.1% FA in deionized water. To facilitate reconstitution, the mixture was vortex-mixed for 1 minute followed by sonication for 5 minutes before being transferred to a 250 ⁇ vial and capped. All vials were centrifuged at 5,000 rpm for 5 min and an aliquot of 25 ⁇ was injected for LC/MS/MS analysis.
  • test samples 100- ⁇ of sample was transferred into individual 16x100 mm screw cap glass test tubes. A 10 ⁇ aliquot of deionized water was then transferred to each tube. A 50 ⁇ aliquot of lidocaine internal standard solution was transferred to each tube and vortexed to mix. Test samples were then processed the same as calibration standards and quality control samples mentioned above.
  • the reaction mixture was cooled to room temperature and DCM (2565 ml) was charged and stirred for 15 minutes. The layers were separated and the aqueous was extracted with DCM (1860 ml). The organic layers were combined and charged to the flask with water (4930 ml). The pH was adjusted to 1 by the addition of concentrated HC1 (280 ml). The layers were separated and the aqueous layer was washed with DCM (1860 ml).
  • the aqueous layer was charged to the flask with DCM (4340 ml) and adjusted to pH8 by the addition of 50 % aq. NaOH (185 ml). The layers were separated and the aqueous layer was extracted with DCM (1860 ml). The organic layers were combined and washed with water (3285 ml), dried over MgS0 4 (660 g), filtered and concentrated to isolate a pale yellow oil.
  • the crude material was purified by silica gel chromatography (30 equivalents) and the product was eluted using ethyl acetate.
  • Anion exchange resin Amberlyst A-26 hydroxide form (28.2 g) was soaked in methanol (100 ml) for 10 minutes with swirling/rotation and filter; it was then rinsed with 2 x 100 ml methanol. The rinsed resin was suspended in methanol (470 ml) and carcainium chloride from step 2 was added as a solution in methanol (4.7 g, 94 ml). The mixture was rotated/gently agitated without grinding for 1.5 hours, with simultaneous testing of the solution above the resin for pH > 8.
  • the resin was filtered and rinsed with 2 x 100 ml methanol and the liquors were reduced in vacuo at 35 °C, following which a solid of carcainium hydroxide formed. Yield of 80 %, HPLC purity 98.8 %.
  • Carcainium hydroxide (7 g, 6.56 g active, 0.02 mol) as a solution in methanol (240 ml) was stirred whilst a steady stream of the desired acid solution (1M, 1 equivalent, 20 ml), in methanol for organic acids (oxalic acid, maleic acid, fumaric acid or xinafoic acid) or 1 : 1 methanol/water for inorganic acids (sulfuric acid or hydrobromic acid), was charged. The mixture was stirred for 5 minutes and the liquors were pH tested. A pH of 4-5 was taken to indicate completion of the reaction. The solution was then evaporated to dryness, yielding a solid and/or a gum.
  • the xinafoate was isolated by concentration in vacuo. Attempts to lyophilise led to oil and emulsion formation. Chemical purity by HPLC: 99.1%.
  • the X H NMR spectrum indicated stoichiometry of 1 : 1. XRPD pattern of the 1 -hydroxy-2-naphthoate did not contain any reflections and confirming that the xinafoate is amorphous.
  • the carcainium salts were characterized by X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA). The results are summarized in Table 2 below.
  • Example 2 A stability study was performed using carcainium salts prepared in Example 1 within a convection oven equilibrated to 80 °C. Approximately 4 mg of each salt was weighed into a small glass vial. This operation was replicated such that two x 4 mg samples of each were available for isolation and testing by HPLC without sampling, after 1 day and after 7 days. The headspace in each vial was not relevant as the vessel was open to the oven (> 99 % airspace above sample within the confines of the glass). The oven was open to ambient via a bleed valve. Samples were capped prior to submission for analysis by HPLC and cooled to ambient. All salts remained visually unimpaired. Purities by HPLC are shown in Table 3 below.
  • Example 1 where milled.
  • the jet-mill was driven by compressed nitrogen supplied at 7 bar. Venturi and grind pressures were set at 90 psi and 60 psi (50 psi for sulfate), respectively, and each candidate salt was passed through the jet- mill once only.
  • the salts were measured by laser diffraction fitted with a dry powder dispersal unit (Malvern Mastersizer 2000 & Sciroco 2000). The results are provided in Table 5 below.
  • Table 5 The result in Table 5 demonstrate that over 90% of the milled material had a particle size of less than 5 ⁇ for all salt forms.
  • Powder X-ray diffraction was performed using a Bruker D8 Advance instrument in reflection geometry using Cu K al radiation with an incident beam monochromator. The instrument was calibrated against a NIST standard of Corundum (NIST 1976). The samples were analysed as-received on a zerobackground Silicon sample holder, which was spun during analysis.
  • the xinafoate was not analysed as it is amorphous.
  • the X-ray diffraction patterns for the unmilled salts were compared to the milled salts. In all cases, peaks were observed in the same places for the unmilled salts as the milled salts, indicating that there is no change in the crystalline phase caused by milling.
  • DSC analysis was performed on a TA Instruments Q2000 equipped with a Tzero cell purged at a constant purge flow rate of 50 ml/minute with dry Nitrogen, and with a RCS 90 cooling system.
  • the instrument was calibrated using Indium as a standard. Between 3 and 5 mg of the samples were weighed into a TAI Tzero Aluminium pan with a pierced lid placed on top prior to being heated from -20 °C to 300 °C at 10 °C per minute, unless otherwise specified in the figure caption.
  • TGA was performed on a TA Instruments Q5000 equipped with an ultrasensitive balance and an infrared furnace purged with dry Nitrogen at a constant flow rate of 10 mL/minute for the reference and 25 mL/minute for the sample.
  • the weight calibration was performed using a certified 100 mg calibration weight.
  • the temperature calibration was performed using Alumel® and Nickel standards. Approximately 7 mg of the samples were weighed into TAI 100 uL Platinum sample pan/holders prior to being heated from ambient temperature to 300 °C at a rate of 10 °C per minute.
  • Example 4 assessment of suitability of salts for use in pressurized metered dose inhalers
  • Formulations were visually assessed for dispersion, flocculation type, sedimentation rate, and sedimentation height. Based on this visual assessment, the rankings for suitability for use in pMDIs set out in Table 6 below were determined.
  • the fumarate, maleate and oxalate salt forms were not suitable for use in suspension pMDIs, due to aggregation of the salt, formation of a poor dispersion and rapid sedimentation.
  • the xinafoate, bromide, sulfate and chloride salts were considered suitable for use in suspension pMDIs.
  • the bromide, sulfate and chloride salts were further tested for aerosol performance.
  • the bromide, sulfate and chloride salts were tested for aersolisation quality on a next generation impactor.
  • the fine particle fraction (FPF) and doses (salt) measured our set out in Table 7 below.
  • Conscious male guinea pigs 350-600g were placed in individual perspex cylindrical exposure chambers with airflow of 1.5 L/minute and allowed to acclimatize.
  • cough responses were induced by exposing animals to citric acid aerosol (0.3 M) generated by an ultrasonic nebuliser at a nebulisation rate of 0.1 ml/minute for 5 minutes (EMKA, France).
  • Coughs were counted throughout the 5 minute citric acid exposure and for a further 10 minutes. Individual coughs were detected in three ways: 1) via a pressure transducer attached to the exposure chamber amplified and recorded using the IOX (version 1.7.0) data acquisition system, 2) via a microphone placed inside the chamber amplified and recorded using IOX, and 3) via visual observation of the animal.
  • IOX version 1.7.0
  • Coughs were counted by a trained observer and were distinguished from responses by the characteristic changes in pressure in the chamber and by visual observation. Animals were removed from the exposure chamber and allowed to recover before being returned to the animal house. Animals were given at least 96 hours to recover between exposures to citric acid and could be challenged up to 4 times. Drug exposure
  • Animals (263 -342 g) were placed in custom built perspex exposure chamber with 4 arms. After acclimatisation, animals were exposed to nebulised (Devilbiss 99) solutions of vehicle (saline), carcainium salt (10 mg/mL). Animals were then removed and placed in the cough chambers. The time interval between post aerosol exposure and commencement of citric acid (12.6 g in 200 ml; 0.3 M) challenge to induce cough was between +25, +31, +37 and + 43 min post saline or drug challenge.
  • the carcainium salts were dissolved in 0.9 % saline.
  • the xinafoate was relatively insoluble in 0.9 % saline, consequently, solutions were prepared in 4.7 % solutol (1.40 g solutol and 10 mg/mL.
  • Guinea-pigs were challenged with different salts of carcainium chloride in a 4 arm exposure chamber for 20 minutes. None of the carcainium salts caused any change in respiratory rate, breathing difficult or tussive responses in 8/8 animals exposed to 10 mg/mL of each salt.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition pharmaceutique liquide destinée à être utilisée dans un inhalateur doseur pressurisé (IDP), la composition comprenant un sel d'addition pharmaceutiquement acceptable de (i) carcaïnium et de (ii) acide sulfurique, acide chlorhydrique, acide bromhydrique, acide maléique ou acide 1-hydroxy-2-naphtoïque (acide xinafoïque).
PCT/GB2013/052325 2012-09-06 2013-09-05 Compositions pharmaceutiques liquides Ceased WO2014037726A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
PCT/GB2012/052191 WO2013034910A1 (fr) 2011-09-06 2012-09-06 Compositions à inhaler
GBPCT/GB2012/052191 2012-09-06
GBGB1304501.8A GB201304501D0 (en) 2011-09-06 2012-09-06 Liquid pharmaceutical compositions
PCT/GB2012/052190 WO2013034909A1 (fr) 2011-09-06 2012-09-06 Traitement de la toux et de quintes de toux
GBPCT/GB2012/052190 2012-09-06
GB1304501.8 2013-03-13

Publications (1)

Publication Number Publication Date
WO2014037726A1 true WO2014037726A1 (fr) 2014-03-13

Family

ID=49162173

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2013/052325 Ceased WO2014037726A1 (fr) 2012-09-06 2013-09-05 Compositions pharmaceutiques liquides

Country Status (1)

Country Link
WO (1) WO2014037726A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217933A1 (fr) 2018-05-10 2019-11-14 The University Of Louisville Research Foundation, Inc. Inhibiteurs de l'oncoprotéine ras, leurs procédés de préparation et leurs méthodes d'utilisation
US11642372B2 (en) 2020-05-01 2023-05-09 Tygrus, LLC Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
US11826382B2 (en) 2020-05-01 2023-11-28 Tygrus, LLC Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
US12042514B2 (en) 2020-05-01 2024-07-23 Tygrus, LLC Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
US12194045B1 (en) 2023-06-26 2025-01-14 Verona Pharma Plc Particulate composition
US12409180B2 (en) 2022-02-21 2025-09-09 Verona Pharma Plc Formulation production process

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6362197B1 (en) * 1998-06-09 2002-03-26 Cardiome Pharma Corp. Compositions and method for treatment of cough

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6362197B1 (en) * 1998-06-09 2002-03-26 Cardiome Pharma Corp. Compositions and method for treatment of cough

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J J ADCOCK ET AL: "RSD931, a novel anti-tussive agent acting on airway sensory nerves", BRITISH JOURNAL OF PHARMACOLOGY, vol. 138, no. 3, 1 February 2003 (2003-02-01), pages 407 - 416, XP055042457, ISSN: 0007-1188, DOI: 10.1038/sj.bjp.0705056 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL278596B1 (en) * 2018-05-10 2025-01-01 Univ Louisville Res Found Inc RAS oncoprotein inhibitors, methods for preparing and methods for using them
CN112312901A (zh) * 2018-05-10 2021-02-02 路易斯维尔大学研究基金会有限公司 Ras癌蛋白抑制剂及其制备方法和使用方法
EP3790541A4 (fr) * 2018-05-10 2022-02-16 University of Louisville Research Foundation, Inc. Inhibiteurs de l'oncoprotéine ras, leurs procédés de préparation et leurs méthodes d'utilisation
WO2019217933A1 (fr) 2018-05-10 2019-11-14 The University Of Louisville Research Foundation, Inc. Inhibiteurs de l'oncoprotéine ras, leurs procédés de préparation et leurs méthodes d'utilisation
IL278596B2 (en) * 2018-05-10 2025-05-01 Univ Louisville Res Found Inc RAS oncoprotein inhibitors, methods for preparing and methods for using them
CN112312901B (zh) * 2018-05-10 2024-05-14 路易斯维尔大学研究基金会有限公司 Ras癌蛋白抑制剂及其制备方法和使用方法
AU2019265011B2 (en) * 2018-05-10 2025-01-30 University Of Louisville Research Foundation, Inc. Inhibitors of the RAS oncoprotein, methods of making and methods of use thereof
US11642372B2 (en) 2020-05-01 2023-05-09 Tygrus, LLC Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
US12042514B2 (en) 2020-05-01 2024-07-23 Tygrus, LLC Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
US11826382B2 (en) 2020-05-01 2023-11-28 Tygrus, LLC Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
US12409180B2 (en) 2022-02-21 2025-09-09 Verona Pharma Plc Formulation production process
US12194045B1 (en) 2023-06-26 2025-01-14 Verona Pharma Plc Particulate composition
US12251384B1 (en) 2023-06-26 2025-03-18 Verona Pharma Plc Particulate composition

Similar Documents

Publication Publication Date Title
US20140242174A1 (en) Treating cough and tussive attacks
US6362197B1 (en) Compositions and method for treatment of cough
US9308200B2 (en) Dry powder formulation comprising a phosphodiesterase inhibitor
WO2014037726A1 (fr) Compositions pharmaceutiques liquides
EP1996552A1 (fr) Sel d'amantadine de montélukast
US20150238456A1 (en) Methods and compositions for administration of oxybutynin
US11434194B2 (en) Amorphous form of vilanterol trifenatate and processes for the preparation thereof
JP2004513099A (ja) 喘息を治療するためのトルテロジンの使用
WO2014037727A1 (fr) Sels de carcaïnium
WO2010097114A1 (fr) Nouvelle combinaison d'agents thérapeutiques
US20120101076A1 (en) Carbonate derivatives for the treatment of cough
JP2006506402A (ja) 四級アンモニウム化合物およびその抗ムスカリン薬としての使用
AU2013368298B2 (en) Methods and compositions for administration of oxybutynin
JP2006511494A (ja) 抗ムスカリン剤としてのキヌクリジニウム誘導体
JP2021191777A (ja) 結晶多形および医薬組成物
JP2021105029A5 (fr)
WO2005044233A1 (fr) Promedicaments n-oxyde d'anesthesiques locaux destines au traitement de l'inflammation pulmonaire associee a l'asthme, a la bronchite et a la bpco
JPWO2004087150A1 (ja) 医薬組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13760089

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13760089

Country of ref document: EP

Kind code of ref document: A1